The AVL9 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from the human near-haploid HAP1 cell line, engineered for targeted disruption of the AVL9 gene. This loss-of-function model enables robust investigation of AVL9??s role in cell migration, actin cytoskeleton dynamics, and focal adhesion regulation. The polyclonal nature avoids clonal selection bias, providing a reproducible system for functional assays without the need for single-cell cloning.
HAP1 cells are a widely adopted near-haploid fibroblast-like line originating from the KBM-7 chronic myeloid leukemia cell line. They exhibit a male karyotype, BCR-ABL1 positivity, and adherent morphology. The near-haploid genome simplifies genetic manipulation and eliminates complications from allelic variation, establishing HAP1 as a premier platform for haploid genetic screens and loss-of-function studies. This background is especially suited for examining genes involved in adhesion, migration, and cytoskeletal organization, offering a clean genetic context for AVL9 knockout.
AVL9 remains a poorly characterized protein implicated in cell migration, likely functioning through modulation of actin cytoskeleton dynamics and focal adhesion turnover. It is thought to act downstream of integrin-mediated adhesion and growth factor stimulation, potentially interacting with focal adhesion scaffold proteins such as vinculin and talin, as well as actin-binding proteins profilin and cofilin. AVL9 signaling may operate within the integrin?CFAK?CSrc?Cp130Cas?CCrk?CDOCK180?CRac1 axis, converging on the WAVE complex to control actin polymerization. Additionally, post-transcriptional regulation by miR-124 further highlights its tight control during migratory processes.
Knockout of AVL9 in the HAP1 cell line is anticipated to yield clear migratory and cytoskeletal phenotypes due to the haploid background, where loss of a single allele produces a functional null. This model enables precise dissection of AVL9 function in a leukemic-derived context, relevant to both hematological malignancy and general mesenchymal migration mechanisms. The near-haploid genome facilitates unambiguous genotype?Cphenotype correlations, making it ideal for screens linking AVL9 loss to specific defects in focal adhesion dynamics and actin organization.
These cells are designed for diverse applications including Transwell migration and invasion assays, wound healing, immunofluorescence analysis of F-actin and focal adhesion markers, and western blotting for phospho-FAK and actin regulators. Live-cell imaging and flow cytometry for adhesion molecules further extend utility. Additionally, the AVL9 knockout population supports haploid genetic screens for synthetic lethality or migration modulators, and drug sensitivity profiling of anti-metastatic compounds. The AVL9 Knockout HAP1 Polyclonal Cells thus provide a versatile platform for migration and adhesion research. For further information, please contact Ascent Research.
